Recent studies have shown that combining venetoclax with small-molecule inhibitors (such as FLT3 inhibitors, MCL-1 inhibitors, and cyclin-dependent kinase 9 inhibitors) has a synergistic effect in the treatment of high-risk AML [34–37]. This evidence concerns the gene MCL1 and acute myeloid leukemia.